[Edaily Reporter Kwon Oh-seok] #Aptabio announced on the 16th that it has received approval from the U.S. Food and Drug Administration (FDA) to lift the clinical hold and resume Phase 1 clinical trials for "ABF-101," an oral treatment for age-related macular degeneration. Following receipt of this official notice, the company plans to resume the previously suspended clinical trials and drug administration.
Disclosure Plus
Aptabio Lifts Hold on Phase 1 Clinical Trial for 'ABF-101'
Kwon Oh Seok
2026-06-16 11:57:54
Economy
Corporation
IT·Science
Economy
"AI Acts as a Savings Coach"... K Bank Launches "AI Goal Savings"
KakaoBank Corp. has launched a savings product featuring an artificial intelligence (AI) coaching function.
KakaoBank Corp. announced on the 13th that it is launching “AI Goal Savings,” a flexi…
Corporation
From Snack Companies to Tofu Makers, Everyone’s Obsessed with ‘Kim’… Here’s Why
Food companies are focusing their efforts on seaweed, often referred to as the “black semiconductor.” They are entering the market by establishing joint ventures or investing in technology for land-ba…
IT·Science
KRAFTON to Hire Over 100 New Graduates… Largest Open Recruitment in Company History
KRAFTON(259960)is hiring more than 100 new graduates. This is the company’s largest-ever open recruitment drive for new graduates, and it will select candidates across six job categories ranging from …
